News Focus
News Focus
icon url

FeMike

03/19/25 2:54 PM

#755219 RE: flipper44 #755213

The damages are based upon the times listed in the complaint, and that does not include now.



Mmm.......I wouldn't be so sure about that.

If this were to go to trial, I would imagine the concept of restricting damages to only the days on which spoofing occurred will be a topic under extreme scrutiny. Again, I don't think it goes to trial. But I would think that this possibility is something that would be considered by both parties in potential settlement discussions, especially considering the landscape of things happening in similar cases.
icon url

Red_Right_Hand

03/19/25 3:04 PM

#755226 RE: flipper44 #755213

The damages are based upon the times listed in the complaint, and that does not include now.



I'm not saying this is their strategy, or that I agree with this strategy if it is their strategy, but if they are negotiating with Ds for a settlement based upon the time frame of spoofing described in the current lawsuit, and during these negotiations they are also asserting that data collection is and has been ongoing, and they have additional evidence of spoofing happening after the time frame covered in the current lawsuit, and are prepared to file a second lawsuit to cover spoofing occurring during the later time frame (between the current lawsuit time frame up until now), then perhaps this could pressure one or more Ds to pay up to settle not only the first lawsuit, but also to not be named in the second lawsuit not yet filed. Perhaps.

Personally, I'd rather them communicate their ongoing progress and allow the share price to rise, than for them to stay quiet to keep the share price low because they believe it may help in their settlement negotiations.
icon url

Investor082

03/19/25 5:53 PM

#755260 RE: flipper44 #755213

Without significant non dilutive funding and FDA approval with reimbursements in the US, this company has no chance of succeeding. That’s what the MMs are betting on. UK approval (particularly without reimbursement approval) will not generate free cash flow. And the company will stay in penny land forever. Endless dilution in store!